Lactate dehydrogenase A (LDHA) is an important enzyme in fermentative glycolysis, generating most energy for cancer cells that rely on anaerobic respiration even under normal oxygen concentrations. This renders LDHA a promising molecular target for the treatment of various cancers. Several efforts have been made recently to develop LDHA inhibitors with nanomolar inhibition and cellular activity, some of which have been studied in complex with the enzyme by X-ray crystallography. In this work, we present a molecular dynamics (MD) study of the binding interactions of selected ligands with human LDHA. Conventional MD simulations demonstrate different binding dynamics of inhibitors with similar binding affinities, whereas steered MD simulations yield discrimination of selected LDHA inhibitors with qualitative correlation between the in silico unbinding difficulty and the experimental binding strength. Further, our results have been used to clarify ambiguities in the binding modes of two well-known LDHA inhibitors.
References
[1]
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
[2]
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297–308.
[3]
Warburg O (1956) On respiratory impairment in cancer cells. Science 124: 269–270.
[4]
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.
[5]
Banga I, Szent-Gyorgyi A, Vargha L (1932) The coenzyme of lactic acid oxidation. Hoppe Seylers Z Physiol Chem 210: 228–235.
Granchi C, Bertini S, Macchia M, Minutolo F (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17: 672–697.
[8]
Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, et al. (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8: 626–635.
[9]
Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107: 2037–2042.
[10]
Goldman RD, Kaplan NO, Hall TC (1964) Lactic Dehydrogenase in Human Neoplastic Tissues. Cancer Res 24: 389–399.
[11]
Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, et al. (2003) Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877–885.
[12]
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway–a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24: 4301–4308.
[13]
Kolev Y, Uetake H, Takagi Y, Sugihara K (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 15: 2336–2344.
[14]
Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, et al. (2010) Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol 23: 45–53.
[15]
Granchi C, Roy S, Giacomelli C, Macchia M, Tuccinardi T, et al. (2011) Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem 54: 1599–1612.
[16]
Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, et al. (1988) Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta 173: 89–98.
[17]
Read JA, Winter VJ, Eszes CM, Sessions RB, Brady RL (2001) Structural basis for altered activity of M- and H-isozyme forms of human lactate dehydrogenase. Proteins 43: 175–185.
[18]
Ward RA, Brassington C, Breeze AL, Caputo A, Critchlow S, et al. (2012) Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J Med Chem 55: 3285–3306.
[19]
Kohlmann A, Zech SG, Li F, Zhou T, Squillace RM, et al. (2013) Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem 56: 1023–1040.
[20]
Dragovich PS, Fauber BP, Corson LB, Ding CZ, Eigenbrot C, et al. (2013) Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. Bioorg Med Chem Lett 23: 3186–3194.
[21]
Fauber BP, Dragovich PS, Chen J, Corson LB, Ding CZ, et al. (2013) Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. Bioorg Med Chem Lett 23: 5533–5539.
[22]
Deck LM, Royer RE, Chamblee BB, Hernandez VM, Malone RR, et al. (1998) Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J Med Chem 41: 3879–3887.
[23]
McClendon S, Zhadin N, Callender R (2005) The approach to the Michaelis complex in lactate dehydrogenase: the substrate binding pathway. Biophys J 89: 2024–2032.
[24]
Dunn CR, Wilks HM, Halsall DJ, Atkinson T, Clarke AR, et al. (1991) Design and synthesis of new enzymes based on the lactate dehydrogenase framework. Philos Trans R Soc Lond B Biol Sci 332: 177–184.
[25]
Colizzi F, Perozzo R, Scapozza L, Recanatini M, Cavalli A (2010) Single-molecule pulling simulations can discern active from inactive enzyme inhibitors. J Am Chem Soc 132: 7361–7371.
[26]
Mai BK, Viet MH, Li MS (2010) Top leads for swine influenza A/H1N1 virus revealed by steered molecular dynamics approach. J Chem Inf Model 50: 2236–2247.
[27]
Jarzynski C (1997) Nonequilibrium Equality for Free Energy Differences. Phys Rev Lett 78: 2690–2693.
[28]
Park S, Schulten K (2004) Calculating potentials of mean force from steered molecular dynamics simulations. J Chem Phys 120: 5946–5961.
[29]
Gore J, Ritort F, Bustamante C (2003) Bias and error in estimates of equilibrium free-energy differences from nonequilibrium measurements. Proc Natl Acad Sci U S A 100: 12564–12569.
[30]
Park S, Araghi F, Tajkhorshid E, Schulten K (2003) Free energy calculation from steered molecular dynamics simulations using Jarzynski's equality. J Chem Phys 119: 3559–3566.
[31]
Rebecca KS, Jill EG (1999) Molecular Dynamics Simulations of L-Lactate Dehydrogenase: Conformation of a Mobile Loop and Influence of the Tetrameric Protein Environment. J Mol Model 5: 153–168.
[32]
Swiderek K, Paneth P (2010) Importance of the lactate dehydrogenase quaternary structure in theoretical calculations. J Phys Chem B 114: 3393–3397.
[33]
Nicolini P, Frezzato D, Gellini C, Bizzarri M, Chelli R (2013) Toward quantitative estimates of binding affinities for protein-ligand systems involving large inhibitor compounds: a steered molecular dynamics simulation route. J Comput Chem 34: 1561–1576.
[34]
Torrie GM, Valleau JP (1977) Nonphysical sampling distributions in Monte Carlo free-energy estimation: Umbrella sampling. J Comput Phys 23: 187–199.
[35]
Swiderek K, Marti S, Moliner V (2012) Theoretical studies of HIV-1 reverse transcriptase inhibition. Phys Chem Chem Phys 14: 12614–12624.
[36]
Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12–21.
[37]
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455–461.
[38]
Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668–1688.
[39]
Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712–725.
[40]
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157–1174.
[41]
Dupradeau FY, Cezard C, Lelong R, Stanislawiak E, Pecher J, et al. (2008) R.E.DD.B.: a database for RESP and ESP atomic charges, and force field libraries. Nucleic Acids Res 36: D360–367.
[42]
Vanquelef E, Simon S, Marquant G, Garcia E, Klimerak G, et al. (2011) R.E.D. Server: a web service for deriving RESP and ESP charges and building force field libraries for new molecules and molecular fragments. Nucleic Acids Res 39: W511–517.
[43]
Bayly CI, Cieplak P, Cornell W, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. The J Phys Chem 97: 10269–10280.
[44]
Cieplak P, Cornell WD, Bayly C, Kollman PA (1995) Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteins. J Comput Chem 16: 1357–1377.
[45]
Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput 4: 435–447.
[46]
Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089–10092.
[47]
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. The Journal of Chemical Physics 103: 8577–8593.
[48]
Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126: 014101.
[49]
Berendsen HJC, Postma JPM, Gunsteren WFv, DiNola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics 81: 3684–3690.
[50]
Hess B (2007) P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation. Chem Theory Comput 4: 116–122.
[51]
Hoover WG (1985) Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A 31: 1695–1697.
[52]
Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys 52: 7182–7190.
[53]
Eszes CM, Sessions RB, Clarke AR, Moreton KM, Holbrook JJ (1996) Removal of substrate inhibition in a lactate dehydrogenase from human muscle by a single residue change. FEBS Lett 399: 193–197.
